Vaccine composition
AssigneeTurnstone Limited Partnership
InventorsDavid F. Stojdl, John Cameron Bell, Brian Lichty
Life of this patent
Estimating the term…
Abstract
There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
Claims13
A method of inducing an immune response against a cancer in a mammal, said cancer being a tumour expressing an HPV protein, said method comprising:
- a) administering a first virus comprising a nucleic acid capable of expressing an HPV tumour associated antigen, wherein said first virus is capable of generating immunity to said HPV tumour associated antigen;
- b) administering a second virus, said second virus being a Vesiculovirus, said second virus comprising a nucleic acid capable of expressing an HPV tumour associated antigen,
- wherein said second virus is capable of providing a therapeutic oncolytic effect in said mammal;
- wherein said first virus is immunologically distinct and physically isolated from said second virus;
- and
- wherein the amino acid sequence of the HPV tumour associated antigen comprises the amino acid sequence of SEQ ID NO. 7.
Dependencies are inferred from the claim text.